CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients.

Cancer Chemother Pharmacol 2013 Feb 26;71(2):301-6. Epub 2012 Oct 26.

OnkoZentrum, Klinik im Park, Zurich, Switzerland.

Background: Endoxifen serum concentrations seem to correlate with outcome in breast cancer (BC) patients. Concurrently, cytochrome P450 2D6 (CYP2D6) enzyme activity and dextromethorphan (DM) metabolism are deemed a surrogate marker for the formation of endoxifen. Here, we conducted a matched cohort study to determine the impact of an extensive CYP2D6 phenotype on relapse in patients with early-stage estrogen receptor (ER)-positive BC and adjuvant tamoxifen intake.

Methods: CYP2D6 extensive metabolism was determined upon appropriate dextromethorphan/dextrorphan (DM/DX) urinary excretion ratios (≤0.30). Fifty-nine BC patients were identified as extensive phenotype metabolizers, while for 148 matched controls, CYP2D6 was not determined. Patients and controls did not differ with respect to age, stage, hormone receptor status, HER2, grade, menopausal status, chemotherapy and antihormonal therapy. Survival analysis was performed according to clinical follow-up.

Results: Disease-free survival (DFS) of patients identified as extensive CYP2D6 metabolizers did not differ significantly from controls (p = 0.10). However, when patients with ER expression of ≤ 20 % were excluded from the analysis, DFS was associated with a more favorable outcome (p = 0.06).

Conclusions: This study suggests a positive association between extensive CYP2D6 metabolism and outcome in early-stage ER-positive BC patients using tamoxifen and in particular, when a sufficient number ERs are represented on the primary tumor.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-2003-yDOI Listing
February 2013
9 Reads

Publication Analysis

Top Keywords

extensive cyp2d6
12
breast cancer
8
patients
8
cancer patients
8
identified extensive
8
patients identified
8
cyp2d6 phenotype
8
cyp2d6
7
extensive
5
patients controls
4
controls differ
4
differ respect
4
determined patients
4
status chemotherapy
4
matched controls
4
controls cyp2d6
4
cyp2d6 determined
4
respect age
4
age stage
4
receptor status
4

References

(Supplied by CrossRef)

TL Lash et al.
Lancet Oncol 2009

K Kiyotani et al.
J Clin Oncol 2010

MP Goetz et al.
Clin Oncol 2005

RS Punglia et al.
J Natl Cancer Inst 2008

MJ Higgins et al.
Annu Rev Med 2011

MP Goetz et al.
Clin Cancer Res 2011

J Gjerde et al.
Ann Oncol 2008

S Borges et al.
J Clin Pharmacol 2010

Y Jin et al.
J Natl Cancer Inst 2005

W Schroth et al.
JAMA 2009

B Ratliff et al.
J Natl Cancer Inst 2004

Similar Publications